Clinical Trial Update: Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial evaluating PET-adapted Nivolumab, Bendamustine, Gemcitabine, Vinorelbine in relapsed/refractory Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Gemcitabine (Gemcitabine)
• Vinorelbine (Vinorelbine)
• nivolumab (nivolumab)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN